DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A. T. C. Lunenburg, Femke M. de Man, Didier Meulendijks, Geert W. J. Frederix, Emma Kienhuis, Geert-Jan Creemers, Arnold Baars, Vincent O. Dezentje, Alexander L. T. Imholz, Frank J. F. Jeurissen, Johanna E. A. Portielje, Rob L. H. Jansen, Paul Hamberg, Albert J. ten Tije, Helga J. Droogendijk, Miriam Koopman, Peter Nieboer, Marlene H. W. van de Poel, Caroline M. P. W. MandigersHilde Rosing, Jos H. Beijnen, Erik van Werkhoven, Andre B. P. van Kuilenburg, Ron H. N. van Schaik, Ron H. J. Mathijssen, Jesse J. Swen, Hans Gelderblom, Annemieke Cats, Henk-Jan Guchelaar, Jan H. M. Schellens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1459-1467
Number of pages9
JournalLancet oncology
Volume19
Issue number11
DOIs
Publication statusPublished - 1 Nov 2018

Keywords

  • DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY
  • PHARMACOGENETICS IMPLEMENTATION CONSORTIUM
  • FLUOROURACIL PLUS LEUCOVORIN
  • METASTATIC COLORECTAL-CANCER
  • 5-FLUOROURACIL SENSITIVITY
  • ORAL CAPECITABINE
  • SEVERE TOXICITY
  • PHASE-III
  • VARIANTS
  • RISK

Cite this

Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G-J., Baars, A., Dezentje, V. O., Imholz, A. L. T., Jeurissen, F. J. F., Portielje, J. E. A., Jansen, R. L. H., Hamberg, P., ten Tije, A. J., Droogendijk, H. J., Koopman, M., Nieboer, P., van de Poel, M. H. W., ... Schellens, J. H. M. (2018). DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet oncology, 19(11), 1459-1467. https://doi.org/10.1016/S1470-2045(18)30686-7